InnoPharmax Inc. (TPEX:4172)

Market Cap	1.57B -4.6%
Revenue (ttm)	68.99M +113.6%
Net Income	-184.40M
EPS	-1.71
Shares Out	107.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	260,361
Open	14.55
Previous Close	14.55
Day's Range	14.55 - 19.10
52-Week Range	12.75 - 23.75
Beta	0.05
RSI	51.04
Earnings Date	Aug 10, 2026

About InnoPharmax

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 33
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4172

Financial Performance

In 2025, InnoPharmax's revenue was 68.99 million, an increase of 113.60% compared to the previous year's 32.30 million. Losses were -184.40 million, 85.7% more than in 2024.